These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 38713229)

  • 1. Overexpressing S100A9 ameliorates NK cell dysfunction in estrogen receptor-positive breast cancer.
    Liu Y; Li M; Fang Z; Gao S; Cheng W; Duan Y; Wang X; Feng J; Yu T; Zhang J; Wang T; Hu A; Zhang H; Rong Z; Shakila SS; Shang Y; Kong F; Liu J; Li Y; Ma F
    Cancer Immunol Immunother; 2024 May; 73(7):117. PubMed ID: 38713229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-cell atlas reveals a distinct immune profile fostered by T cell-B cell crosstalk in triple negative breast cancer.
    Ding S; Qiao N; Zhu Q; Tong Y; Wang S; Chen X; Tian Q; Xiao Y; Shen K
    Cancer Commun (Lond); 2023 Jun; 43(6):661-684. PubMed ID: 37158690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers.
    Johnson J; Rychahou P; Sviripa VM; Weiss HL; Liu C; Watt DS; Evers BM
    PLoS One; 2019; 14(3):e0209392. PubMed ID: 30875375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S100A9 expressed in ER(-)PgR(-) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival.
    Bergenfelz C; Gaber A; Allaoui R; Mehmeti M; Jirström K; Leanderson T; Leandersson K
    Br J Cancer; 2015 Oct; 113(8):1234-43. PubMed ID: 26448179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers.
    Yi J; Ren L; Li D; Wu J; Li W; Du G; Wang J
    Biomed Pharmacother; 2020 Apr; 124():109827. PubMed ID: 31986408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On discovery of novel hub genes for ER+ and TN breast cancer types through RNA seq data analyses and classification models.
    Saddiqa A; Zakir M; Sheikh M; Muneer Z; Hassan A; Ali I; Haq IU; Khan AA; Malik A; Siddiqi AR
    Sci Rep; 2024 Sep; 14(1):20840. PubMed ID: 39242688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crumbs protein homolog 3 (CRB3) expression is associated with oestrogen and progesterone receptor positivity in breast cancer.
    Li P; Zhou C; Yan Y; Li J; Liu J; Zhang Y; Liu P
    Clin Exp Pharmacol Physiol; 2019 Sep; 46(9):837-844. PubMed ID: 31087799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
    Wu JR; Zhao Y; Zhou XP; Qin X
    Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer.
    Park IH; Yang HN; Lee KJ; Kim TS; Lee ES; Jung SY; Kwon Y; Kong SY
    Oncotarget; 2017 May; 8(20):32722-32730. PubMed ID: 28415798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of differentially expressed proteins between HER2 positive and triple negative breast cancer and their prognostic significance.
    Wei Z; Sijia F; Rui T; Yang L; Jianjun H; Bin W; Jing X
    Ann Diagn Pathol; 2021 Dec; 55():151834. PubMed ID: 34610510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
    Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
    Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The estrogen/miR-338-3p/ADAM17 axis enhances the viability of breast cancer cells via suppressing NK cell's function.
    Shi Y; Pan J; Hang C; Tan L; Hu L; Yan Z; Zhu J
    Environ Toxicol; 2023 Jul; 38(7):1618-1627. PubMed ID: 37052432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic insights into triple-negative and HER2-positive breast cancers using isogenic model systems.
    Mudvari P; Ohshiro K; Nair V; Horvath A; Kumar R
    PLoS One; 2013; 8(9):e74993. PubMed ID: 24086418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer.
    Sato T; Oshi M; Huang JL; Chida K; Roy AM; Endo I; Takabe K
    Breast Cancer Res Treat; 2024 Nov; 208(2):415-427. PubMed ID: 39017815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of macrophage--cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer.
    Hollmén M; Roudnicky F; Karaman S; Detmar M
    Sci Rep; 2015 Mar; 5():9188. PubMed ID: 25776849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1.
    Engel JB; Honig A; Kapp M; Hahne JC; Meyer SR; Dietl J; Segerer SE
    Arch Gynecol Obstet; 2014 Jan; 289(1):141-7. PubMed ID: 23828443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. All-trans-retinoic acid modulates glycolysis via H19 and telomerase: the role of mir-let-7a in estrogen receptor-positive breast cancer cells.
    El Habre R; Aoun R; Tahtouh R; Hilal G
    BMC Cancer; 2024 May; 24(1):615. PubMed ID: 38773429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated Metabolomics and Transcriptomics Analysis of Anacardic Acid Inhibition of Breast Cancer Cell Viability.
    Piell KM; Poulton CC; Stanley CG; Schultz DJ; Klinge CM
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A majority of circadian clock genes are expressed in estrogen receptor and progesterone receptor status-dependent manner in breast cancer.
    Berkel C; Cacan E
    J Biosci; 2024; 49():. PubMed ID: 39193850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.